From phenotypes to black holes… and back

Dear Editor,

We thank Rajendram et al. [1], who—with an amusing use of a pun—point out a “hole” in our Editorial. This physical and metaphorical hole is clearly the presence of a patent foramen ovale (PFO) as an additional mechanism in the hypoxaemia observed in COVID-19. Although PFO is frequently found in the general population [2], we have not documented any cases in which PFO significant enough to (even partly) explain the hypoxaemia. All our patients undergo echocardiography to exclude structural or functional heart abnormalities that may explain or contribute to respiratory failure (e.g. severe mitral regurgitation or, indeed intracardiac shunt). It is clear that if such an abnormality was to be found—the whole idea of phenotypes is no longer relevant is the hypoxaemia may be explained by intracardiac shunt regardless of presence or absence of COVID-19 [2]. This argument is also valid for any ventilated patient. Therefore, we do not share the enthusiasm of Rajendram et al. [1], to further sub-classify phenotypes. We intended to present a conceptual framework that can aid the selection of the ventilatory strategy, while avoiding the use of multiple and confusing acronyms. We however fully agree with Rajendram et al. that echocardiography is an essential tool for the diagnosis and management of all ventilated patients whether with classical or ‘atypical’ ARDS.

We read with interest the letter by Jain et al. [3], who summarise some of the understanding of the ACE-2-mediated dysregulation of pulmonary perfusion in COVD-19, and delineate an ‘epithelial-endothelial cross-talk’ as a possible mechanism for hypoxaemia. The mechanism they propose is certainly plausible and consistent with the biology of ACE-2 receptors [4, 5] and with some phases of the history of the disease.

However, despite the undeniable temptation to provide a unified mechanism to explain the dysregulated ventilation/perfusion relationship in COVID-19, the interaction between the heterogenous distribution of the disease, the variable amount of pulmonary oedema, the ventilation strategy received and the duration of symptoms, make the search for a single explanatory mechanism simplistic. In addition, inflammation and thrombosis [6] can lead to occlusion of the vasculature that will increase dead space and contribute to the increase in minute ventilation and work of breathing. We disagree, however with Jain et al. when they state that P-SILI is an unlikely mechanism of the worsening of the respiratory function in COVID-19. Indeed, in many institutions the use (sometimes prolonged) of non-invasive support (NIV or CPAP) is a frequent strategy for managing COVID-19 pneumonitis [7, 8]. It is clear that NIV or CPAP will not lead to P-SILI in all instances. If the support is able to reduce the respiratory effort (trans-pulmonary pressure), and the of the disease follows a more benign course the hypoxaemia will resolve. However, uncontrolled work of breathing can lead to additional oedema and lung injury and can explain some of the results found in the literature that describes the outcomes of patients with hypoxemic respiratory failure who undergo initial treatment with non-invasive strategies [9,10,11]. These results may be applicable to COVID-19.

We would like once again to stress the difference between having a conceptual pathophysiological framework versus having an explanatory biological model. Our intention was to suggest the former while recognising the difficulties in describing the latter [12, 13]. The model we describe, whilst based on physiological considerations, has a high degree of pragmatism to suit front-line management and triage decisions in the many patients who have fallen victim of COVID-19 pneumonitis.

References

  1. 1.

    Rajendram R, Kharal GA, Mahmood N (2020) Rethinking the respiratory paradigm of Covid-19: a ‘hole’ in the argument. Intensive Care Med. https://doi.org/10.1007/s00134-020-06102-6

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Mojadidi MK, Ruiz JC, Chertoff J, Zaman MO, Elgendy IY, Mahmoud AN, Al-Ani M, Elgendy AY, Patel NK, Shantha G, Tobis JM, Meier B (2019) Patent foramen ovale and hypoxemia. Cardiol Rev 27:34–40

    Article  Google Scholar 

  3. 3.

    Jain A, Doyle J (2020) Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. https://doi.org/10.1007/s00134-020-06083-6

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ (2018) The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev 98:505–553

    CAS  Article  Google Scholar 

  5. 5.

    Wevers BA, van der Hoek L (2010) Renin-angiotensin system in human coronavirus pathogenesis. Future Virol 5:145–161

    CAS  Article  Google Scholar 

  6. 6.

    Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147

    CAS  Article  Google Scholar 

  7. 7.

    Tobin MJ (2020) Basing respiratory management of coronavirus on physiological principles. Am J Respir Crit Care Med 11:1319–1320

    Article  Google Scholar 

  8. 8.

    Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, Shrestha BR, Arabi YM, Ng J, Gomersall CD, Nishimura M, Koh Y, Du B, Asian Critical Care Clinical Trials Group (2020) Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 8:506–517

    CAS  Article  Google Scholar 

  9. 9.

    Bellani G, Laffey JG, Pham T, Madotto F, Fan E, Brochard L, Esteban A, Gattinoni L, Bumbasirevic V, Piquilloud L, van Haren F, Larsson A, McAuley DF, Bauer PR, Arabi YM, Ranieri M, Antonelli M, Rubenfeld GD, Thompson BT, Wrigge H, Slutsky AS, Pesenti A, LUNG SAFE Investigators, ESICM Trials Group (2017) Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE study. Am J Respir Crit Care Med 195:67–77

    Article  Google Scholar 

  10. 10.

    Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, Llamas N, Alcazar M, Torres A (2012) Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med 38:458–466

    Article  Google Scholar 

  11. 11.

    Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Beduneau G, Deletage-Metreau C, Richard JC, Brochard L, Robert R, FLORALI Study Group, REVA Network (2015) High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 372:2185–2196

    CAS  Article  Google Scholar 

  12. 12.

    Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L (2020) COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. https://doi.org/10.1007/s00134-020-06033-2

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Marini JJ, Gattinoni L (2020) Management of COVID-19 respiratory distress. JAMA. https://doi.org/10.1001/jama.2020.6825

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Open Access funding provided by Projekt DEAL.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Luciano Gattinoni.

Ethics declarations

Conflicts of interest

The authors have no conflict of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Camporota, L., Chiumello, D., Busana, M. et al. From phenotypes to black holes… and back. Intensive Care Med 46, 1498–1499 (2020). https://doi.org/10.1007/s00134-020-06124-0

Download citation